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Quantitative reagentfree detection of fibrinogen levels in human blood
plasma using Raman spectroscopy
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Fibrinogen assays are commonly used as part of clinical screening tests to investigate haemorrhagic
states, for detection of disseminated intravascular coagulation and as a predictor of a variety of
cardiovascular events. The Clauss assay, which measures thrombin clotting time, is the most commonly
used method for measuring fibrinogen levels. Nevertheless, inconsistencies are present in inter
manufacturer reagent sources, calibration standards and methodologies. Automated coagulation analysers,
which measure changes in optical density during the prothrombin time (PTFg), have found use in many
hospitals. However, the PTFg method is found to give falsely elevated values due to varying choices of
calibrants, reagents and analysers. As an alternative, Raman spectroscopy has previously been applied to
the analysis of blood and its various constituents to determine various analyte concentrations such as
glucose, urea, triglycerides and cholesterol. In this study, Raman spectroscopy was investigated for its
ability to accurately quantify fibrinogen concentration in blood plasma. Samples collected from 34
patients were analysed by Raman spectroscopy and the resultant spectra were fitted with a Partial Least
Squares Regression model using target values obtained through a precalibrated Clauss fibrinogen assay.
Various spectral preprocessing methods were utilised to prepare data to be entered into a calibration
model. A root mean square error of prediction of 0.72 ± 0.05 g/L was achieved with as few as 25 spectra.
In this pilot study, Raman spectroscopy has been demonstrated to be a robust technique providing rapid
and reagentfree quantification of fibrinogen levels in blood plasma and a potential alternative to the
Clauss assay.

Introduction
The activation of fibrinogen or Factor I, a 340 kDa dimeric
plasma glycoprotein synthesised in the hepatocytes of the liver, is
involved as an acute phase protein in the pathogenesis of
inflammation, tumour growth and various diseases. During
circulation, fibrinogen is degraded into various molecular
weights, 69.7 % remaining in the original high molecular weight
(HMW) form (340 kDa), 26.5 % as low molecular weight
(LMW’) fibrinogens (305 kDa) and the remaining 3.8% in the
low molecular weight (LMW) configuration of 270 kDa, as a
result of the consecutive removal of a 35 kDa carboxyterminal
polypeptide from one of the Aachains.1 Epidemiological studies
have demonstrated elevated levels of fibrinogen in blood to be an
independent risk factor for cardiovascular and coronary heart
disease2, 3, while low fibrinogen levels are seen as an important
diagnostic physiological variable in pathological conditions
including various haemorrhagic states, disseminated intravascular
coagulation, liver disease and during thrombolytic/defibrination
therapy.4 Fibrinogen concentration has also been shown to be an
independent prognostic parameter in patients diagnosed with
cervical cancer.5
Fibrinogen levels in plasma may be determined through various
methods. These methods are based on different techniques of
detection such as measures of clotting rate6 or clottable protein,7
turbidimetry
(light
scattering
of
the
sample),8
9
10
immunological/antibody and heat/salt precipitation . Assays
based on clotting rates and changes in turbidity/lightscattering
are most commonly used in clinical practice. The Clauss
This journal is © The Royal Society of Chemistry [2012]
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fibrinogen assay, developed in 1957, measures the thrombin
clotting time and remains the most frequently used technique for
fibrinogen measurement. The method entails the addition of
excess thrombin to diluted plasma samples and the subsequent
measurement of the clotting time. The recorded time is compared
with a calibration curve constructed through the measurement of
clotting times from a series of dilutions of reference plasmas of
known fibrinogen concentration, allowing the concentration in
the test sample to be established. Prothrombin timederived (PT
Fg) methods are currently used in approximately 50% of UK
Haematology laboratories11, their popularity being largely due to
the introduction of coagulation automates. The assay measures
the turbidity and lightscattering properties after the complete
clotting of the plasma occurs. The analyser requires calibration
through the recording of the prothrombin time on a series of
plasma dilutions of known fibrinogen concentration and the
subsequent construction of a graph of the change in optical
properties against fibrinogen concentration. The optical response
recorded from the test sample may then be converted to
fibrinogen content. It has also been shown that the LMW and
LMW’ fibrinogens exhibit prolonged clotting times compared
with HMW fibrinogen.12
Despite the popularity of the two assays, several issues have been
raised regarding their reproducibility and standardisation. The
Clauss assay is relatively time consuming with respect to
calibration, requiring sufficient expertise to evaluate difficult end
points from high dilutions of standard plasmas, samples with low
fibrinogen content or those forming unstable clots.4 Analysers
[Analyst], [2012], [137], 1807–1814 | 1
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relying on mechanical, tensile clot strength endpoint detection
may be affected by heparin therapy while photooptical systems
measuring light scattering changes may be vulnerable to slow
fibrin polymerisation, turbid reference plasma samples along with
the presence of any bile pigment or free haemoglobin.4, 13
Inconsistencies arise when fibrinogen levels are measured using
commercial reagents sourced from different manufacturers. For
example, thrombin strength, buffer composition (anticoagulant
inhibitors and degradation products) along with calibration and
dilution methods suggested by the various manufacturers vary
significantly.14 Despite the availability of International Standard
preparations for plasma fibrinogen, some commercial reference
samples have been found to be incorrectly calibrated using
internal laboratory plasma samples or their respective national
standards.15 Substantial differences were also observed depending
on the type of analyser used.
Raman spectroscopy measures vibrational modes in molecules
and can be employed to characterise more complex mixtures of
molecules. The spectrum of a complex biological mixture of
proteins is composed of contributions from each of the major
components in that mixture, and changes in the concentration of
one or more components in that mixture will give rise to
reproducible changes in the Raman spectrum. Both Raman and
infrared spectroscopy, in combination with multivariate statistical
techniques, have previously been investigated as a potential
clinical diagnostic tool to differentiate between normal and
malignant cells1618 as well as tissues from the skin, breast,
prostate, oesophagus and cervix.1923 Furthermore, it has been
demonstrated that vibrational spectroscopy has the ability to
quantify various analyte concentrations (total protein, glucose,
urea, triglycerides and cholesterol etc.) in blood and its fluid
derivatives.2432 In contrast to current assay approaches, which
rely on physicochemical means of determining fibrinogen,
vibrational spectroscopy provides detailed chemical information
of the biological compounds, each possessing unique spectral
signatures. Rohleder et al. compared midinfrared spectroscopy to
Raman spectroscopy with respect to the analysis of various blood
serum constituents including total protein content24 and the
strengths and weaknesses of each technique were addressed
(sample preparation, operational parameters etc.). Significantly it
was found that Raman spectroscopy can quantify the total protein
content with lower root mean square errors of prediction than
corresponding midinfrared spectroscopic results. While Raman
spectroscopy has been used previously to establish total protein
content in blood serum, 24, 31, 33 the current pilot study attempts to
distinguish and quantify the single component of fibrinogen in
dried, undiluted, whole human blood plasma collected from
patients. Being able to determine changes in protein levels in
whole blood samples compared to serum has the potential
advantage of minimising sample processing. Although fibrinogen
is a minor component of the total protein content (~4%), the
ability to correlate sample dependent variations in content,
through a regression model relating changes in spectroscopic
signatures to the gold standard Clauss assay, promises a potential
alternative routine screening assay. Spectral data was therefore
collected and modelled using a partial least squares regression
algorithm, correlating values to those obtained in parallel using a
precalibrated Clauss Fibrinogen assay.

www.rsc.org/xxxxxx | XXXXXXXX
60

65

70

75

80

Blood Plasma Preparation
Venous blood from 34 patients was collected in BD Vacutainer™
Plus plastic trisodium citrate tubes. After eight inversions, each
tube was centrifuged at 1500g for 15 minutes to separate the
plasma and cellular components. Samples were immediately
stored at 20 °C until needed. Prior to measurement, the
microtubes were thawed in a 37 °C water bath and 10 mL of
plasma carefully spotted in 0.75 x 0.75 cm2 squares onto pre
cleaned calcium fluoride windows (Crystran Ltd., UK).
Table 1. Performance of Clauss Fibrinogen Assay (HemosIL®
FibrinogenC ACL Top Family)

Normal Range

Sample Number
119

Range (g/L)
2.38 – 4.98

Normal Control
Low Control
Linearity

Mean Fibrinogen
(g/L)
3.03
1.07
0.35 – 10

CV %
(run to run)
4.5
5.1

CV %
(day to day)
5.5
6.8

The plasma squares were then passively dried at room
temperature for at least 4 hours in a desiccator filled with a silica
gel desiccant. Fibrinogen content was determined using a pre
calibrated HemosIL® FibrinogenC ACL Top Family Clauss
assay; performance values provided by the manufacturer are
listed in Table 1. The fibrinogen content recorded from patient
samples ranged from 0.60 to 8.18 g/L. Crystalline purified
Fibrinogen from human plasma, used as a comparative control for
the spectral measurements, and was purchased from Sigma
Aldrich®, UK.

Instrumentation
Raman Measurements
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Raman spectra were recorded on a Horiba JobinYvon
(Villeneuve d'Ascq, France) HR800 LabRam Raman
spectrometer (LabSpec V5.0 software) using a 785 nm diode
laser source (~110 mW at the sample), focussed onto the sample
through a 100x objective lens (NA=0.9, MPlan, Olympus).
Raman scatter was collected in a backscattered configuration
through a 100 μm confocal aperture onto a spectrograph/Peltier
cooled Synapse CCD detector. A 300 line/mm grating was used
to scan a spectral region between 400 – 1800 cm1, achieving a
dispersion of ~1.5 cm1 per pixel. Calibration was performed with
reference to the 520.7 cm1 peak of crystalline Si, and spectra
were corrected for detector dark noise, system optics and system
spectral response through the use of a Raman Intensity Correction
Standard (SRM 2241, NIST). Spectra were recorded from a
square array of 10 x 10 points (totalling 100) spaced 2 μm apart
using 30 ´ 3 second acquisition periods per point. The array was
collected from the homogenous middle of the dried plasma
square.
FTIR Measurements

105

Parallel infrared absorption spectroscopic imaging was carried
out using the same dried plasma squares on CaF2 windows on a
Perkin Elmer (Waltham, Massachusetts, USA) Spotlight 400N
FTIR imaging system equipped with a linear array of 16 liquid
nitrogen cooled MCT detectors. A 25 mm x 25 mm pixel

EXPERIMENTAL PROCEDURES
2 | The Analyst, [2012], [137], 1807–1814
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resolution was used to capture an average absorption image in
transmission mode.
Data Analysis
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A host of preprocessing techniques were trialled in various
combinations on the raw dataset to produce an equally weighted
input into the regression model for reducing prediction errors.
Methods included combinations of a SavitzkyGolay smoothing
filter, vector normalisation, linear/polynomial baseline offset
correction and extended multiplicative scatter correction. All pre
processing methods were performed using Matlab™ v7.7
(Mathworks, Natick, Massachusetts) in conjunction with PLS
Toolbox 5.22 (Eigenvector Research, Wenatchee, WA).
A common method for creation of calibration models for
prediction of target analyte concentrations with vibrational
spectra is Partial Least Squares Regression (PLSR).29, 31, 34, 35 The
PLS model attempts to elucidate factors or latent variables (LV)
which account for the systematic majority of variation in
predictors ‘X’ (spectral data) versus associated responses ‘Y’
(target values of fibrinogen concentration). In other words, PLS
uses the information contained in Y to determine the systematic
multivariate signatures in X. This is achieved through the
reduction of the variables corresponding to the wavenumber axis
of the spectral data X into reduced number of spectral variables
while simultaneously reducing variables containing associated
target concentration information Y in each training sample.
Latent variables that are best correlated with variations in target
values allow the creation of a calibration model that can
subsequently be tested using test data. The linear regression
model is created by reducing the X and Y matrices into latent
variables and scores via principal component analysis (PCA) such
that the X matrix scores are regressed against the Y matrix scores
in the model. The process can therefore be described
mathematically as:
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remaining objects in the dataset (the calibration set), and
subsequent application of the resulting model to the test set. This
ensures each subvalidation experiment robustly tests a model
using objects which are independent of those used to construct
the model. In this study, two cross validation methods were used
for comparative purposes: Random sample cross validation,
which chooses different random subset test sets determined
through the random selection of n/s objects in the data set (where
n is the total number of objects in the dataset and s is the
predetermined number of data splits), such that no single object
appears in more than one test set. This procedure is repeated for a
user defined number of iterations. In this study, a split of s = 5
was chosen and the process was iterated 100 times. The second
method is LeaveOneOut cross validation, involves the use of a
single element from the data set being used as a test or validation
‘set’ while the remaining objects are used as the training set. This
process is iteratively repeated so that every single observation in
the data set is used once as the designated validation data set.
The SIMPLS algorithm 36 of the PLS Toolbox v5.22 (Eigenvector
Research, Inc.) was implemented within Matlab. The training of
the teaching data set was optimised by calculating the rootmean
square error of calibration (RMSEC) and the rootmeansquare
error of cross validation (RMSECV). The spectral data obtained
from the 33 samples were split 60/40 into training and test sets
respectively. The various RMSE were calculated according to
equations 3, 4 and 5 below:

Ntrain

å (x

RMSEC =

pred , i

2

- yresp , i )

i =1

(3)

Ntrain - LV - 1

80

X = TP’ + E

(1)

Y = UQ’ + F

(2)

Ntrain
35

å (x

pred , i

40

i =1

RMSECV =

where; X and Y = Matrices of the predictors and responses
respectively.

Ntest

U = Matrix of Y – scores

å (x

pred, i

RMSEP =

(4)

Ntrain

T = Matrix of X – scores

P = Matrix of X – latent variables

2

- yresp , i )

- yresp, i )

i=1

Ntest

2

(5)

Q = Matrix of Y – latent variables
E = X – residual errors
85

F = Y – residual errors

45

50

Cross validation is a technique enabling the assessment of the
optimal complexity of a model (in this case the number of latent
variables in the PLS model) thus allowing an estimation of the
performance of a model when applied to unknown data. Cross
validation involves a series of subvalidation experiments, which
see the removal of a subset of objects (or spectra) from a dataset
for testing (the test set), construction of a model using the

This journal is © The Royal Society of Chemistry [2012]
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Here, xpred,i and yresp,i correspond to fibrinogen content in sample i
determined by Raman spectral data and the Clauss assay,
respectively. Ntrain and Ntest denotes the number of training (Ntrain
= 20 x n spectra) and test samples (Ntest = 14 x n spectra)
respectively. The number of latent variables used for the PLS
calibration is optimised by finding the value that corresponds to
the minimum of the RMSECV. Using the training values, a
model is constructed and the quality of fit is judged by how well

The Analyst, [2012], [137] , 1807–1814| 3

Table 2. Peak assignments37 for the Raman spectra of blood plasma.
Peak Position (cm1)
540
621
642
758
829
853
878
939
958
1003
1032
1082
1128
1158
1175
1208
1271
1318
1339
1447
1552
1585
1606
1616
1659
a

5

Assignments of Raman Vibrational Modes
Histidinea
C–C twisting mode of phenylalanine
C–C twisting mode of tyrosine
Symmetric ring breathing of tryptophan
Out of plane ring breathing tyrosine
Ring breathing mode of tyrosine
Arginine*
C–C stretching mode backbone (ahelix conformation)
CH3 deformation
Symmetric ring breathing mode of phenylalanine
C–H inplane bending mode of phenylalanine
C–N stretching mode
C–N stretching mode
C–C / C–N stretching mode
C–H inplane bending mode of tyrosine
Tryptophan and phenylalanine n(C–C6H5) mode
Amide III (C–N stretching mode, mainly ahelix conformation)
C–H deformation
C–H deformation
C–H deformation
Tryptophan
C=C stretching
C=C stretching mode of phenylalanine and tryptophan
C=C stretching mode of tyrosine and tryptophan
Amide I (C=O stretching mode of proteins, ahelix conformation)

Tentative assignments.

it is able to predict the values from the test data set. The root
meansquared error of calibration (RMSEC) and the rootmean
squared error of prediction (RMSEP) are used to evaluate the
predictive capacity of the constructed model. The efficacies of the
various preprocessing and validation methods were evaluated
through the performance of the PLS model.
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While water possesses a low Raman scattering cross section in
the visible region, it is resonantly enhanced in the near infrared
due to the onset of OH vibrational overtones.38 Furthermore, as it
has only been mildly centrifuged, the protein rich blood plasma
scatters significantly, introducing a large background to the
spectrum which swamps the Raman signal of the solute.39
Therefore dried samples were chosen over fresh/wet samples.
However, the drying process resulted in inhomogeneous samples
as constituents precipitated predominantly at the edge of the
spotted square either through surface tension or molecular weight
differences. Figure 1 shows an FTIR image illustrating this
sample inhomogeneity in terms of spectrally averaged
absorbance. These variable thicknesses produced Raman spectra
of various intensities and backgrounds due to differences in
sample density crosssections.
To maintain a level of consistency, Raman spectra were always
recorded from the middle of the dried spot as it was the largest
area of consistent thickness and uniformity. Figure 2 shows the
mean Raman spectrum of dried blood plasma (top) (smoothed,
baseline corrected and normalised) together with a spectrum of
crystalline purified Fibrinogen from human plasma (bottom)
(SigmaAldrich®, UK) for spectral comparison. Total plasma
proteins (albumin and globulin) are the most abundant species in
blood plasma and hence spectra are characteristic of these protein
base vibrations. The observed peaks primarily show the
This journal is © The Royal Society of Chemistry [2012]

45

tyrosine/phenylalanine twisting doublet at 621/642 cm1 while the
tyrosine ringbreathing doublet can be seen at 829/860 cm1. The
sharpest and most dominant peak at 1003 cm1 is attributed to the
phenylalanine symmetric breathing mode while CH2 bending
appears at 1446 cm1 and the C=O stretching mode of Amide I at
1657 cm1. The Raman spectrum of crystalline fibrinogen
contains similar features, but notably has strong contributions
from tryptophan at 758 cm1 and 1552 cm1. This is surprising as
fibrinogen does not have a high tryptophan content, but may be
due to sample impurities or alignment of tryptophan moieties in
the crystalline sample. A full list of peak assignments is provided
in Table 2.
Spectral Preprocessing
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Despite the improvements over the low signaltonoise
limitations associated with the analysis of wet plasma samples,
the dried plasma films still exhibited inconsistencies evident in
the variable backgrounds seen in the raw spectral data (Figure 3).
Although fluorescence is a possible origin of such backgrounds,
the collection of blood plasma involves gradient and
centrifugation separation, which should have removed all cellular
material, including red blood cells and therefore there should be
no hemeproteins in the sample. Such backgrounds have also
been demonstrated to be the result of Mielike scattering of both
the source laser and the Raman bands themselves which enters
the spectrometer as uncollimated stray light, together with
variable contributions due to spot to spot sample morphology. 37
Therefore, the application of spectral preprocessing or corrective
methodologies was an integral step to ensure that robust and
precise quantitative information may be extracted from the
Raman dataset.
Smoothing of the spectra was carried out using a SavitzkyGolay
filter40 to remove any spurious peaks and as dried plasma films
generally produced spectra with a relatively high signaltonoise
[Analyst], [2012], [137], 1807–1814 | 4
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10

ratio, a 3rd order, five data point window proved sufficient.
Baseline offset correction was seen to be a crucial preprocessing
step due to the large variation in background seen in the raw data.
A polynomial baseline function was used and compared with an
iterative, linearnodal correction (written inhouse). For
polynomial correction, bandfree regions between wavenumber
ranges of 400 – 630 cm1 and 1502 – 1800 cm1 were chosen,
while the linearnodal correction was executed in both automated
node selection mode as well as manually, using the same
specified regions above. Vector normalisation is a standard
method in which the total intensity of the spectral dataset is
considered rather than individual peaks. This is achieved by
calculating the sum of the
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0.7
0.6

multiplicative effects from spectra was Extended Multiplicative
Scattering Correction (EMSC).41 EMSC is a combination
corrective algorithm dealing with both additive and multiplicative
background effects of each sample spectrum originally developed
for Fourier Transform Infrared spectroscopy.
PLS
Two different datasets were used as the observed predictors (X)
for the PLS algorithm; one utilised the entire original spectral
dataset (100 spectra per sample), while the other was composed
of an average, intersampled matrix to explore model efficiency
with a reduced, averaged dataset. The intersampling process was
carried out through a fourpoint moving window average of the
full dataset, reducing 100 spectra per sample to 25 averaged
spectra. Intersampling, as we found, reduces the effect of outliers
in the final result. Therefore, after random sorting of the datasets,
the training matrices were 2040 and 510 spectra (60% split) for
the full and averaged intersampled datasets respectively, with the
remaining 40% split being designated as test matrices (1360 and
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200
0.2
250

0.1
0
50

100

150

200

250

300

Microns
15

Figure 1. Average FTIR absorbance image showing inhomogeneous
sample distribution. The scaled colour bar indicates that zero absorption
occurs at 0 while maximum absorption occurs at 1.
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Figure 3. Raw spectra (n = 3400) obtained from all dried blood plasma
samples.
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Figure 2. Typical spectrum of human blood plasma (top) and spectrum of
purified crystalline human fibrinogen (bottom).
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squared intensity values of the spectrum and using the squared
root of this sum as the normalisation constant. Each variable of a
spectrum is then divided by this constant. Figure 4 shows vector
normalisation applied to the averaged intersampled dataset. The
data processing procedure has removed much of the variability of
the raw spectra of Figure 3. All spectra were retained for the
regression model to mimic as best as possible an automated
sampling technique.
An alternative technique applied in order to remove
This journal is © The Royal Society of Chemistry [2012]

Wavenumber (cm )
Figure 4. Average intersampled dataset (n = 850) after smoothing,
automated linear‐nodal baseline correction and vector normalisation.

55

340 spectra respectively). Out of the 100 iterations, Figure 5
shows an example of a single iteration of RMSEC and RMSECV
against the number of latent variables from the PLS analysis
showing, in this case the minimum RMSECV to occur at LVmin =
15. Once the model algorithms were sufficiently trained,
validation of the model performance was carried out using the
The Analyst, [2012], [137] , 1807–1814| 5
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unseen, test matrices.
The fibrinogen concentrations from the 14 test sample sets were
predicted by the constructed PLS model and evaluated against
target values obtained by the Clauss fibrinogen assay. The
random nature of the crossvalidation procedures resulted in the
generation of different values of LVmin and hence prediction
errors. Therefore, the model was trained and executed 100
separate times (with associated randomisation and splitting of the
data on each run) to produce minimum, maximum and average
values of LVmin, RMSEP and R2 with associated variances

Root Mean Square Error (g/L)

1.8

45

50

model using the full dataset, a filtering technique was developed
for the removal of outliers. Firstly, PCA was employed to
determine the principal component. The scores of each sample
were then plotted onto a threedimensional space and the mean
centroid was determined from the resultant cluster. The sample(s)
with the furthest calculated squared Euclidean distance from the
centroid are deemed outliers and omitted from the dataset. The
furthest three, five and ten outliers were removed in this fashion.
However, predictive errors were actually slightly increased (data
not shown). This indicated that the selected outliers, which were

RMSECV
RMSEC

1.6
1.4

RMSECV

min

= LV

min

1.2
1
0.8
0.6

0

5

10

15

20

25

Latent Variables

15

Figure 5. An example plot of the root mean square error of calibration
(RMSEC) versus root mean square error of cross validation as a function
of the number of latent variables. The optimum number of latent
variables corresponds to the minimum of RMSECV.
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Figure 6. Performance of the PLS calibration model and subsequent test
set prediction using the full spectral dataset.

60

Figure 7. Performance of the PLS calibration model and subsequent test
set prediction using the average intersampled spectral dataset.
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The predictive performances of the models show a close
correlation between the concentrations predicted by Raman
spectroscopy and target concentrations established by the Clauss
Fibrinogen assay. As can be seen from Figure 6, the wide scatter
in predicted Fibrinogen concentrations using the full spectral
dataset prevents an accurate classification of samples as either
moderate but normal Fibrinogen concentrations (1.7 – 4.0 g/L as
determined through clotting assays)42 or high clinically
significant values (e.g. 7 – 9 g/L). Furthermore, it is notable that
the best fit regression does not extrapolate to the origin. The
average intersampled dataset (n = 25 per sample) visually appears
to contain less data scatter with less influence from outliers
resulting in a stronger correlation coefficients (Figure 7), thus
improving prediction to £ 0.25 g/L over the full dataset (Table 3).
Extrapolation towards zero fibrinogen content was also more
accurate within the averaged dataset. As previously mentioned,
the intersampling process was carried out through a fourpoint
moving window average of the full dataset, which effectively
reduced the influence of outliers. This may also imply that there
are a threshold number of spectral replicates needed from a
sample to accurately represent the biochemical content and to
achieve quantification of a target constituent. However, on
average, more latent variables or factors were required to explain
variations in the spectral data and target values using the
averaged, intersampled dataset (mean LVmin = 20) than the full
dataset (mean LVmin = 15).
In an attempt to improve the performance of the calibration
6 | The Analyst, [2012], [137], 1807–1814
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70

deemed as such based on the loadings or intrasample variable
relationships, still contributed in some way to the construction of
the model.
The two crossvalidation procedures chosen produced slightly
different prediction accuracies. While LeaveOneOut cross
validation is a commonly used technique, it has a tendency to
produce overly optimistic results for larger datasets (n > 20) and
be prone to the replicate sample trap (replicates of the same
sample existing in both the training and the test set).43, 44 The
random sample selection cross validation method provides more
This journal is © The Royal Society of Chemistry [2012]

5

realistic results and is more adaptable in that it may be used on
many types of datasets with the advantage of avoiding the
replicate sample trap through the use of a lower number of splits
and an increased number of iterations. However, the random
nature of the latter method might lead to different researchers
producing different PLS models of the same data.

This journal is © The Royal Society of Chemistry [2012]
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Table 3. Results of calibration and prediction PLS models using the test set. Values are averaged over 100 runs each with associated standard deviations.
(LOOCV = LeaveOneOut Cross Validation, RanCV = Random Cross Validation)

nLVmin
20.
20
20
18
20
20
21
21

Average intersampled Dataset (n = 850, 25 spectra per sample)
RMSEC (g/L)
RMSEP (g/L)
R2 Calibration
Polynomial Baseline,Vector Normalised LOOCV
0.38 ± 0.04
0.75 ± 0.05
0.98 ± 5E3
Polynomial Baseline,Vector Normalised RanCV
0.41 ± 0.03
0.75 ± 0.05
0.97 ± 4E3
Polynomial Baseline,EMSC LOOCV
0.40 ± 0.08
0.78 ± 0.06
0.97 ± 0.01
Polynomial Baseline,EMSC RanCV
0.44 ± 0.07
0.78 ± 0.05
0.97 ± 0.01
LinearNodal, Vector Normalised LOOCV
0.39 ± 0.06
0.72 ± 0.05
0.97 ± 6E3
LinearNodal, Vector Normalised RanCV
0.42 ± 0.02
0.73 ± 0.06
0.97 ± 4E3
LinearNodal, EMSC LOOCV
0.38 ± 0.05
0.73 ± 0.05
0.98 ± 6E3
LinearNodal, EMSC RanCV
0.40 ± 0.02
0.73 ± 0.06
0.97 ± 2E3

nLVmin

RMSEC

17

0.78 ± 0.03

16

0.81 ± 0.03

17

0.80 ± 0.02

16

0.82 ± 0.02

17

0.77 ± 0.02

16

0.80 ± 0.03

18

0.78 ± 0.02

17

0.80 ± 0.01

Full Dataset (n = 3400, 100 spectra per sample)
RMSEP
R2 Calibration
Polynomial Baseline,Vector Normalised LOOCV
0.98 ± 0.02
0.89 ± 8E3
Polynomial Baseline,Vector Normalised RanCV
0.99 ± 0.02
0.88 ± 9E3
Polynomial Baseline,EMSC LOOCV
0.98 ± 0.02
0.89 ± 7E3
Polynomial Baseline,EMSC RanCV
0.98 ± 0.03
0.88 ± 6E3
LinearNodal, Vector Normalised LOOCV
0.97 ± 0.02
0.90 ± 6E3
LinearNodal, Vector Normalised RanCV
0.98 ± 0.02
0.89 ± 0.01
LinearNodal, EMSC LOOCV
0.98 ± 0.02
0.89 ± 6E3
LinearNodal, EMSC RanCV
0.98 ± 0.02
0.89 ± 4E3

R2 Prediction
0.90 ± 0.01
0.90 ± 0.01
0.90 ± 0.02
0.89 ± 0.01
0.91 ± 0.01
0.91 ± 0.01
0.91 ± 0.01
0.91 ± 0.02

R2 Prediction
0.83 ± 8E3
0.82 ± 9E3
0.83 ± 9E3
0.83 ± 9E3
0.83 ± 9E3
0.83 ± 8E3
0.83 ± 9E3
0.83 ± 9E3

5

10

15

20

25

Concerning the preprocessing of the spectral data before
initiating model training, it is recognised that baseline correction
should be carried out before any normalisation or corrective
procedures to avoid incorporating baseline fluctuations into the
normalisation constant.45 Comparative results are shown
regarding the use of an iterative linearnodal and polynomial
baseline correction algorithm (Table 3 – Supplementary Data).
While the linearnodal correction brought all spectra down to a
common baseline (zero), the polynomial correction method
distributed spectra over a range of wavenumbers, hence the latter
method producing » 5% larger errors in prediction. With respect
to the linearnodal method, the choice between automated node
selection and userspecified nodes saw the former perform better
in terms of the prediction errors produced. This may be explained
in terms of the minute wavenumber shift of nodes in that they
may not necessarily be located in the same region for all spectra
during the correction. Hence the automated selection was a better
choice to account for this.
For the correction of the inherent multiplicative effects of
scattering seen in terms of prediction errors, vector normalisation
outperformed EMSC in the averaged intersampled dataset.
While EMSC visually converged spectra more efficiently, it
8 | The Analyst, [2012], [137], 1807–1814

30

35

40

imposed a detrimental effect in failing to preserve key spectral
features contributing to the training of a better quantitative
predictive model. To avoid intersample crossover effects, each
sample set of spectra (n = 25 or 100) was either normalised or
corrected with EMSC individually rather than applying the
corrections over the entire dataset. As with baseline correction,
the choice of method to correct for multiplicative effects appeared
to be more significant when applied to the averaged intersampled
dataset.
To enable a measure of the model performance versus the stated
precision of the Clauss assay in a clinical context, the coefficients
of variation of the observed prediction errors (CVRMSE) were
calculated (6) and evaluated against the standard deviation of the
reference values (calculated from the mean and relative
coefficient of variation %CV (7)) provided by the manufacturer
(Table 1).

CVRMSE =

RMSE
x

(6)

This journal is © The Royal Society of Chemistry [2012]

%CV =

5
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35

s
x

´ 100

(7)

Where s = standard deviation, xˉ = mean
The precision of the reference assay is described by a standard
deviation of 0.17 and 0.14 for daytoday and testtotest
respectively, as specified by the manufacturer. This is compared
to a CVRMSE of 0.19 (best) and 0.21 (mean) as achieved by
Raman spectroscopic measurements. These figures suggest that
the Clauss assay slightly outperforms the Raman spectroscopic
model with regards to precision or reproducibility in the
measurement of fibrinogen concentration. Ignoring the influence
of outliers, the model shows a calibration accuracy of
approximately 1 g/L and 2 g/L for the test set. Nevertheless, the
case is presented for the technique to be a potential analytical tool
for a frequently required measurement. It is noted that the sample
preparation was somewhat crude, and that the measurements
were made on the thinnest regions of the sample. Improved
sample preparation by for example spin coating could
significantly improve signal to noise and spectral background.
Ultimately, in situ measurements in wet samples would be
desirable.
Attention has to be drawn to the patient samples, which featured
almost 50% of the values below 3 g/L and only three values
above 5 g/L, this reflects the normal healthy range of 2.2 – 4.3
g/L. However, this unbalance not only affected the correlation but
also the errors associated with the constructed model. However,
the choice was made to include all samples without dilution to
maintain the reagentfree nature of the study, ensuring a robust
comparison of the technique to the goldstandard assay. As this is
a pilot study to test the sensitivity of Raman spectroscopy, a
larger sample set of blood samples was not pursued. Of greater
importance was to explore and establish the range of fibrinogen
concentrations to construct a robust model. It is noted that
calibration against a limited gold standard is a process that is in
itself obviously limited. Ultimately, a cross validation against
more precise proteomic techniques would be required.

Conclusions
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This study investigated the potential of Raman spectroscopy to
quantify the Factor I fibrinogen protein in undiluted, dried patient
blood plasma samples. The use of dried blood plasma forgoes the
issues related to background water spectral contributions,
scattering, heating and biohazard safety. Also, the small volume
(10 mL) of plasma needed for analysis means the majority of the
blood sample is retained for parallel tests. Partial Least Squares
regression was employed to construct and train a calibration
model using Raman spectra obtained from plasma samples as
fitted to target fibrinogen values obtained from the Clauss assay.
It was shown that the various spectral preprocessing methods
chosen in this study affected model training performance and
resultant prediction errors. The best predictive result (0.72±0.05
g/L) came with the use of an averaged, intersampled dataset that
had been smoothed using a SavitzkyGolay filter, baseline
corrected using an automated linearnodal algorithm and vector
normalised. While the latter combination of methods worked best
in this particular study, given a different analyte and/or
instrumental setup the preprocessing techniques would no doubt
be suitably modified. Although preprocessing remains an
essential part of Raman spectroscopy, unwanted variability may
This journal is © The Royal Society of Chemistry [2012]
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be introduced through over manipulation of spectral data, which
is especially applicable in sensitive quantitative analysis. Thus
the basic rule of thumb is to ensure to preserve spectral integrity
through the use of only the minimum amount of preprocessing
needed. While the accuracy of Raman spectroscopy failed to
match that of the goldstandard assay in this study, a more
balanced dataset or calibration using certified fibrinogen
standards and controls would possibly improve performance
towards clinical application. However, the number of spectral
replicates and hence acquisition times needs to be reduced for the
purposes of daily routine analysis. It is noted that calibration
against a limited gold standard is a process which is in itself
obviously limited. Ultimately, a cross validation against more
precise proteomic techniques would be required. However, the
study demonstrates that, as a quantitative tool, spontaneous,
unenhanced Raman spectroscopy is a highly reproducible
technique in the detection of single components in a complex
biological matrix.
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